Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Grabs Ex-U.S. Rights To ThromboGenics' Retina Adhesion Therapy Ocriplasmin In $500 Mil. Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis' ophthalmic unit Alcon will collaborate with Belgium's ThromboGenics on the marketing and future development of the vitreomacular adhesion therapy, ocriplasmin.

Advertisement

Related Content

ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea
Jetrea Launch Plans Include 30 Sales Reps, 15 Reimbursement Specialists
Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch
Ophthalmic Advisory Committee To Consider Two New Fields For Drug Therapy
Biopharma Quarterly Deal Statistics, Q1 2012
Bayer Chief Worried About Innovation, Spanish Debts
Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth
ThromboGenics Delays Diabetic Retinopathy Study; On Track To File Ocriplasmin For Retinal Adhesions
Bayer Nails Down Deal To Share Ex-U.S. Rights For Wet AMD Treatment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel